AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18626633 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral propiverine solution (15 mg)
Number of subjects: 10
Study 18626633 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended Release (ER) propiverine
Number of subjects: 10
Study 18626633 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate Release (IR) propiverine
Number of subjects: 10
Study 16199685 — intervention group
Group type: EXPERIMENTAL
Intervention: Clown group (N = 20)
Number of subjects: 40
Study 16199685 — intervention group
Group type: COMPARATOR
Intervention: Control group (N = 20)
Number of subjects: 40
Study 16199685 — intervention group
Group type: EXPERIMENTAL
Intervention: Health professionals' opinion
Number of subjects: 40
Study 16199685 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-evaluation by clowns
Number of subjects: 40
Study 11851645 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaleplon 10 mg
Number of subjects: 13
Study 11851645 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaleplon 20 mg
Number of subjects: 13
Study 11851645 — intervention group
Group type: COMPARATOR
Intervention: Zopiclone 7.5 mg (active control)
Number of subjects: 13
Study 11851645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 10361239 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART + IL-2
Number of subjects: 0
Study 10361239 — intervention group
Group type: COMPARATOR
Intervention: HAART
Number of subjects: 0
Study 7536481 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (250,000 KIU added to cardiopulmonary bypass prime solution and 250,000 KIU infused intravenously over 30 minutes before bypass)
Number of subjects: 100
Study 7536481 — intervention group
Group type: COMPARATOR
Intervention: Control (0.9% saline in equal volumes at identical times)
Number of subjects: 100
Study 7536481 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 100
Study 7536481 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 100
Study 1911011 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation induction of anaesthesia with isoflurane and nitrous oxide in oxygen with 5% carbon dioxide
Number of subjects: 50
Study 1911011 — intervention group
Group type: COMPARATOR
Intervention: Inhalation induction of anaesthesia with isoflurane and nitrous oxide in oxygen without 5% carbon dioxide
Number of subjects: 50
Study 7126396 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimization of heat loss using a hot-water humidifier, hot-water circulating mattress, and warming all i.v. fluids
Number of subjects: 0
Study 7126396 — intervention group
Group type: COMPARATOR
Intervention: Standard surgical and anaesthetic techniques (control group)
Number of subjects: 0
Study 29514333 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine infusion
Number of subjects: 12
Study 29514333 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 12
Study 29514333 — intervention group
Group type: COMPARATOR
Intervention: Infusion-end plasma morphine concentrations
Number of subjects: 12
Study 29777633 — intervention group
Group type: COMPARATOR
Intervention: Daily terbutaline (8 × 0.5 mg) with habitual training
Number of subjects: 67
Study 29777633 — intervention group
Group type: COMPARATOR
Intervention: Daily terbutaline (8 × 0.5 mg) with resistance training
Number of subjects: 67
Study 29777633 — intervention group
Group type: COMPARATOR
Intervention: Daily terbutaline (8 × 0.5 mg) with endurance training
Number of subjects: 67
Study 26797412 — intervention group
Group type: EXPERIMENTAL
Intervention: HP‐HMB (high‐protein oral nutritional supplement)
Number of subjects: 652
Study 26797412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 652
Study 25309985 — intervention group
Group type: EXPERIMENTAL
Intervention: SenseWear Armband (SWA)
Number of subjects: 20
Study 22827919 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational diabetes mellitus (GDM) diagnosis
Number of subjects: 848
Study 22827919 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient visits
Number of subjects: 848
Study 22827919 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal intensive care unit (NICU) use
Number of subjects: 848
Study 22827919 — intervention group
Group type: EXPERIMENTAL
Intervention: Delivery costs
Number of subjects: 848
Study 20667004 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorphenamine (100 μg kg⁻¹)
Number of subjects: 24
Study 20667004 — intervention group
Group type: COMPARATOR
Intervention: Saline (100 μg kg⁻¹)
Number of subjects: 24
Study 17189799 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof SN60‐AT intraocular lens (IOL)
Number of subjects: 61
Study 17189799 — intervention group
Group type: COMPARATOR
Intervention: Akreos Adapt intraocular lens (IOL)
Number of subjects: 61
Study 15203060 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitch discrimination task with 400 and 4000 Hz tone pips presented to the right or left ear.
Number of subjects: 0
Study 15203060 — intervention group
Group type: EXPERIMENTAL
Intervention: Laterality discrimination task with 400 and 4000 Hz tone pips presented to the right or left ear.
Number of subjects: 0
Study 15203060 — intervention group
Group type: COMPARATOR
Intervention: Control session with 400 or 4000 Hz tone alone presented at the left or right ear.
Number of subjects: 0
Study 12188480 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented fixation
Number of subjects: 501
Study 12188480 — intervention group
Group type: COMPARATOR
Intervention: Cementless fixation
Number of subjects: 501
Study 12188480 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented and Cementless fixation
Number of subjects: 501
Study 10451784 — intervention group
Group type: EXPERIMENTAL
Intervention: Saquinavir-SGC 1200 mg administered 3 times daily
Number of subjects: 88
Study 10451784 — intervention group
Group type: COMPARATOR
Intervention: Hard gelatin capsule (HGC) formulation 600 mg administered 3 times daily
Number of subjects: 88
Study 8904053 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of pethidine after atropine premedication (pre‐sedated group)
Number of subjects: 1077
Study 8904053 — intervention group
Group type: COMPARATOR
Intervention: Atropine alone without sedation (non‐sedated group)
Number of subjects: 1077
Study 8904053 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-medicated with pethidine
Number of subjects: 1077
Study 2201327 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat measurement of lumen volume of the femoral artery using a computer-based technique
Number of subjects: 107
Study 55267 — intervention group
Group type: EXPERIMENTAL
Intervention: metisoprinol at the dose of 50 mg/kg/day, divided t.i.d., by mouth for 12 days
Number of subjects: 42
Study 55267 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 42
Study 30450627 — intervention group
Group type: EXPERIMENTAL
Intervention: A. citriodora (total essential oil 1.66 mg/10 ml and total amount of flavonoid in terms of quercetin 3.22 mg/10 ml of the syrup), administered as 10 cc of syrup an hour before bedtime for 4 weeks.
Number of subjects: 100
Study 30450627 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered as 10 cc of syrup an hour before bedtime for 4 weeks.
Number of subjects: 100
Study 29208798 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (RAS patients)
Number of subjects: 42
Study 29208798 — intervention group
Group type: EXPERIMENTAL
Intervention: Group III (RAS with duodenal ulcer)
Number of subjects: 42
Study 29208798 — intervention group
Group type: COMPARATOR
Intervention: Group I (Healthy controls)
Number of subjects: 42
Study 26230903 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc acetate alone as first-line therapy (n=9)
Number of subjects: 26
Study 26230903 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc acetate in association with D-penicillamine (n=4) or Trientine (n=1)
Number of subjects: 26
Study 26230903 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc acetate as maintenance therapy after D-penicillamine (n=12)
Number of subjects: 26
Study 26230903 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc acetate (general)
Number of subjects: 26
Study 24102148 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance provision of emergency contraceptive pills (ECP), condoms, and extended information
Number of subjects: 420
Study 24102148 — intervention group
Group type: COMPARATOR
Intervention: Control group (no advance provision of ECP)
Number of subjects: 420
Study 21188849 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 90 mg
Number of subjects: 588
Study 21188849 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg
Number of subjects: 588
Study 21188849 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 2400 mg
Number of subjects: 588
Study 21188849 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen (600 mg/codeine) (60 mg)
Number of subjects: 588
Study 21188849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 588
Study 18601850 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrodin injection (1,000 mg administered via intravenous drip infusion for 4 weeks)
Number of subjects: 63
Study 18601850 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrodin injection
Number of subjects: 63
Study 18601850 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment with conventional hypotensive drugs
Number of subjects: 63
Study 16525098 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 1,000 mg for three days followed by azithromycin 1,000 mg plus chloroquine 600 mg on days 1 and 2, and azithromycin 1,000 mg plus chloroquine 300 mg on day 3
Number of subjects: 40
Study 16525098 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine 600 mg on days 1 and 2, then 300 mg on day 3
Number of subjects: 40
Study 12641516 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide, 200 mg daily for 2 weeks
Number of subjects: 11
Study 12641516 — intervention group
Group type: COMPARATOR
Intervention: Diet alone (control)
Number of subjects: 11
Study 12503891 — intervention group
Group type: EXPERIMENTAL
Intervention: Polycystic ovaries (PCO)
Number of subjects: 42
Study 12503891 — intervention group
Group type: COMPARATOR
Intervention: Normal ovaries
Number of subjects: 42
Study 12503891 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortex and stroma of PCO
Number of subjects: 42
Study 12503891 — intervention group
Group type: COMPARATOR
Intervention: Cortex and stroma of normal ovaries
Number of subjects: 42
Study 9715497 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscoelastic
Number of subjects: 54
Study 9715497 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 54
Study 7800212 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (2500 U, 5000 U, or 10,000 U)
Number of subjects: 35
Study 7800212 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Number of subjects: 35
Study 7800212 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodic saline flushing
Number of subjects: 35
Study 7800212 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellulose diacetate or polyacrylonitrile membranes
Number of subjects: 35
Study 7800212 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 35
Study 2723128 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 150 mg/day for 4 weeks
Number of subjects: 29
Study 1267080 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotional efforts in an experimental group of low-utilizing townships
Number of subjects: 30000
Study 1267080 — intervention group
Group type: EXPERIMENTAL
Intervention: Printed advertisements
Number of subjects: 30000
Study 1267080 — intervention group
Group type: COMPARATOR
Intervention: Control group (no promotional efforts)
Number of subjects: 30000
Study 31504006 — intervention group
Group type: EXPERIMENTAL
Intervention: Ion beam polishing (IBP)
Number of subjects: 0
Study 31504006 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation of the evolution process of morphology
Number of subjects: 0
Study 28609128 — intervention group
Group type: EXPERIMENTAL
Intervention: Dydrogesterone (duphaston®) at 10 mg
Number of subjects: 100
Study 28609128 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized progesterone (utrogestran®) at 100 mg
Number of subjects: 100
Study 26044167 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity blue light treatment (HI: 453 nm LED, 200 mW/cm², n = 24)
Number of subjects: 47
Study 26044167 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity blue light treatment (LI: 453 nm LED, 100 mW/cm², n = 23)
Number of subjects: 47
Study 26044167 — intervention group
Group type: COMPARATOR
Intervention: Contralateral control plaque (untreated)
Number of subjects: 47
Study 24342211 — intervention group
Group type: EXPERIMENTAL
Intervention: MDSC levels in infants with recurrent wheezing
Number of subjects: 31
Study 24342211 — intervention group
Group type: COMPARATOR
Intervention: Bronchopneumonia and preoperative infants (controls)
Number of subjects: 31
Study 21810018 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of bevacizumab (1.25 mg)
Number of subjects: 8
Study 19247780 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of the PICOT approach in framing research questions
Number of subjects: 313
Study 16689808 — intervention group
Group type: EXPERIMENTAL
Intervention: Neat and diluted shampoos
Number of subjects: 0
Study 16689808 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% sodium lauryl sulfate solution
Number of subjects: 0
Study 16689808 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% sodium lauryl sulfate solution
Number of subjects: 0
Study 16689808 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 14586586 — intervention group
Group type: COMPARATOR
Intervention: Elderly subjects
Number of subjects: 12
Study 11451043 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy
Number of subjects: 24
Study 11451043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 11451043 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine concentration
Number of subjects: 24
Study 9290025 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombotic microangiopathy present in the acute stage of the disease in the colon, pancreas, brain, spleen, liver.
Number of subjects: 64
Study 9290025 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrarenal alterations associated with ARF-hyperhydration of organs and tissues.
Number of subjects: 64
Study 9290025 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrarenal alterations induced by ARF treatment.
Number of subjects: 64
Study 29315164 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training Group (STG) - 10 weeks of strength training including plyometric, sprint, and resistance training, performed twice weekly in addition to normal running.
Number of subjects: 25
Study 29315164 — intervention group
Group type: COMPARATOR
Intervention: Control Group - continued regular training without additional strength training.
Number of subjects: 25
Study 29315164 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training Group (STG)
Number of subjects: 25
Study 27555187 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal epidural block (CEB, 0.75 mL/kg of 0.25% bupivacaine)
Number of subjects: 80
Study 27555187 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonography-guided transversus abdominis plane (TAP) block (0.5 mL/kg of 0.25% bupivacaine)
Number of subjects: 80
Study 27555187 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal epidural block (CEB)
Number of subjects: 80
Study 27555187 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonography-guided transversus abdominis plane (TAP) block
Number of subjects: 80
Study 24722560 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii 750 mg/day for 6 weeks
Number of subjects: 72
Study 24722560 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 22251037 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% Silver Diamine Fluoride (SDF)
Number of subjects: 91
Study 22251037 — intervention group
Group type: COMPARATOR
Intervention: Interim Restorative Treatment (IRT) using FUJI IX
Number of subjects: 91
Study 19291566 — intervention group
Group type: EXPERIMENTAL
Intervention: Macintosh video laryngoscope (MVL)
Number of subjects: 25
Study 19291566 — intervention group
Group type: COMPARATOR
Intervention: Conventional Macintosh 3 (Mac3) blade
Number of subjects: 25
Study 16365195 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG strain present in patients
Number of subjects: 8696
Study 16365195 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG strain in multivariable analyses
Number of subjects: 8696
Study 15115992 — intervention group
Group type: EXPERIMENTAL
Intervention: Median sternotomy
Number of subjects: 511
Study 15115992 — intervention group
Group type: COMPARATOR
Intervention: Video-assisted thoracoscopy
Number of subjects: 511
Study 11484954 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (100 mg/m2) + Mitoxantrone (20 mg/m2) + G-CSF (150 mcg/m2/d s.c.)
Number of subjects: 54
Study 11484954 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel + Mitoxantrone + G-CSF
Number of subjects: 54
Study 9667123 — intervention group
Group type: EXPERIMENTAL
Intervention: Chymopapain injection
Number of subjects: 11
Study 9667123 — intervention group
Group type: COMPARATOR
Intervention: Automated percutaneous discectomy
Number of subjects: 11
Study 9667123 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical discectomy
Number of subjects: 11
Study 8112187 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (2.5 g/day, five 1-g fish oil capsules each containing 0.5 g omega-3 fatty acids)
Number of subjects: 20
Study 8112187 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (2.5 g/day)
Number of subjects: 20
Study 8112187 — intervention group
Group type: COMPARATOR
Intervention: Safflower oil (control group)
Number of subjects: 20
Study 3381757 — intervention group
Group type: EXPERIMENTAL
Intervention: Dieting (caloric restriction)
Number of subjects: 115
Study 3381757 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (increased caloric expenditure)
Number of subjects: 115
Study 3381757 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 115
Study 30689476 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance (group U, n=112)
Number of subjects: 208
Study 30689476 — intervention group
Group type: COMPARATOR
Intervention: Nerve stimulation (group N, n=96)
Number of subjects: 208
Study 30335127 — intervention group
Group type: EXPERIMENTAL
Intervention: HR
Number of subjects: 469
Study 30335127 — intervention group
Group type: EXPERIMENTAL
Intervention: RMSTD
Number of subjects: 469
Study 30335127 — intervention group
Group type: EXPERIMENTAL
Intervention: HR+RMSTD
Number of subjects: 469
Study 28237506 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant medication (specific medications not detailed)
Number of subjects: 447
Study 26149971 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilization splint (SS)
Number of subjects: 40
Study 26149971 — intervention group
Group type: EXPERIMENTAL
Intervention: Nociceptive trigeminal inhibition splint (NTI)
Number of subjects: 40
Study 24043739 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) after local excision (LE)
Number of subjects: 1010
Study 24043739 — intervention group
Group type: COMPARATOR
Intervention: Local excision (LE) without radiotherapy
Number of subjects: 1010
Study 24043739 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive local recurrence
Number of subjects: 1010
Study 21518677 — intervention group
Group type: EXPERIMENTAL
Intervention: Bare metal stents (BMS)
Number of subjects: 682
Study 21518677 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass surgery (CABG)
Number of subjects: 682
Study 21518677 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus drug-eluting stents (SES)
Number of subjects: 682
Study 21518677 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 682
Study 21518677 — intervention group
Group type: COMPARATOR
Intervention: SES
Number of subjects: 682
Study 21518677 — intervention group
Group type: COMPARATOR
Intervention: BMS
Number of subjects: 682
Study 17852303 — intervention group
Group type: EXPERIMENTAL
Intervention: Sliding Hip Screw (SHS)
Number of subjects: 1344
Study 17852303 — intervention group
Group type: COMPARATOR
Intervention: Gamma Nail
Number of subjects: 1344
Study 17983467 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy modalities to inactivate myofascial trigger points (MTrPs)
Number of subjects: 100
Study 17983467 — intervention group
Group type: COMPARATOR
Intervention: Wait-and-see strategy (control group)
Number of subjects: 100
Study 15105026 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid fortification of enriched cereal grains
Number of subjects: 77
Study 11700398 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glutamine
Number of subjects: 26
Study 11700398 — intervention group
Group type: COMPARATOR
Intervention: Isonitrogenous control amino acid solution
Number of subjects: 26
Study 9578795 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified oxygen headbox
Number of subjects: 0
Study 9578795 — intervention group
Group type: COMPARATOR
Intervention: Conventional eye patches
Number of subjects: 0
Study 8035473 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexpert
Number of subjects: 81
Study 8035473 — intervention group
Group type: COMPARATOR
Intervention: Video
Number of subjects: 81
Study 8035473 — intervention group
Group type: COMPARATOR
Intervention: Self-help book
Number of subjects: 81
Study 8035473 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 81
Study 3499182 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalargin (1-4 mg)
Number of subjects: 9
Study 3499182 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalorphine (5 mg)
Number of subjects: 9
Study 3499182 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NaCl solution)
Number of subjects: 9
Study 31201877 — intervention group
Group type: EXPERIMENTAL
Intervention: Numerical Rating Scale (NRS) worst
Number of subjects: 22
Study 31201877 — intervention group
Group type: EXPERIMENTAL
Intervention: Numerical Rating Scale (NRS) average
Number of subjects: 22
Study 31201877 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Respiratory Questionnaire
Number of subjects: 22